Novartis (NYSE: NVS) reported earnings on July 17. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q2), Novartis beat slightly on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue increased slightly. Non-GAAP earnings per share shrank. GAAP earnings per share dropped.

Margins dropped across the board.

Revenue details
Novartis logged revenue of $14.49 billion. The 10 analysts polled by S&P Capital IQ expected a top line of $14.31 billion on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $1.30. The five earnings estimates compiled by S&P Capital IQ anticipated $1.32 per share. Non-GAAP EPS of $1.30 for Q2 were 5.8% lower than the prior-year quarter's $1.38 per share. GAAP EPS of $1.01 for Q2 were 9.0% lower than the prior-year quarter's $1.11 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 67.5%, 80 basis points worse than the prior-year quarter. Operating margin was 20.2%, 190 basis points worse than the prior-year quarter. Net margin was 17.1%, 160 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
Next quarter's average estimate for revenue is $14.07 billion. On the bottom line, the average EPS estimate is $1.34.

Next year's average estimate for revenue is $57.34 billion. The average EPS estimate is $5.14.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,460 members out of 1,508 rating the stock outperform, and 48 members rating it underperform. Among 442 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 428 give Novartis a green thumbs-up, and 14 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Novartis is outperform, with an average price target of $80.28.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.